AC Immune (ACIU) is trading down at $2.71 (-0.55%), as of the latest quote. It operates in the Health Care sector.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | CHF 23.2M | CHF 20.3M | CHF 6.91M | CHF 110.5M | CHF 15.4M | CHF 0 | CHF 3.94M | CHF 14.8M | CHF 27.3M | CHF 3.57M |
| Growth (year over year) | −40.6% | −12.7% | −65.9% | +1498.0% | −86.0% | −100.0% | — | +276.1% | +84.5% | −86.9% |
| Operating income | −CHF 10.5M | −CHF 22.5M | −CHF 49.5M | CHF 44.5M | −CHF 61.3M | −CHF 79.0M | −CHF 70.8M | −CHF 53.6M | −CHF 52.4M | −CHF 69.3M |
| Operating margin | −45.0% | −111.3% | −716.9% | 40.3% | −397.0% | — | −1800.4% | −362.3% | −191.8% | −1940.1% |
| Net income | −CHF 7.10M | −CHF 26.4M | −CHF 51.0M | CHF 45.4M | −CHF 61.9M | −CHF 73.0M | −CHF 70.8M | −CHF 54.2M | −CHF 50.9M | −CHF 70.4M |
| Net margin | −30.6% | −130.4% | −737.1% | 41.1% | −401.3% | — | −1798.0% | −366.4% | −186.4% | −1971.6% |
| EPS (diluted) | −CHF 0.14 | −CHF 0.46 | −CHF 0.82 | CHF 0.64 | −CHF 0.86 | −CHF 0.97 | −CHF 0.85 | −CHF 0.64 | −CHF 0.51 | −CHF 0.70 |
| Balance sheet | ||||||||||
| Cash and equivalents | CHF 152.2M | CHF 124.4M | CHF 156.5M | CHF 193.6M | CHF 160.9M | CHF 82.2M | CHF 31.6M | CHF 78.5M | CHF 36.3M | CHF 26.8M |
| Total assets | CHF 156.1M | CHF 132.0M | CHF 196.6M | CHF 299.3M | CHF 238.7M | CHF 261.4M | CHF 185.9M | CHF 182.8M | CHF 230.9M | CHF 154.3M |
| Total liabilities | CHF 13.7M | CHF 15.2M | CHF 18.9M | CHF 26.8M | CHF 23.3M | CHF 29.5M | CHF 16.9M | CHF 22.2M | CHF 118.6M | CHF 109.4M |
| Shareholders' equity | CHF 142.4M | CHF 116.8M | CHF 177.6M | CHF 272.4M | CHF 215.5M | CHF 232.0M | CHF 169.0M | CHF 160.6M | CHF 112.3M | CHF 44.9M |
| Cash flow | ||||||||||
| Operating cash flow | −CHF 5.65M | −CHF 22.1M | −CHF 44.1M | CHF 55.2M | −CHF 59.5M | −CHF 65.7M | −CHF 73.6M | −CHF 60.4M | CHF 65.8M | −CHF 69.3M |
| Capital expenditure | CHF 899.0K | CHF 1.80M | CHF 1.86M | CHF 1.89M | CHF 1.71M | CHF 2.63M | CHF 1.24M | CHF 801.0K | CHF 576.0K | CHF 900.0K |
| Free cash flow | −CHF 6.54M | −CHF 23.9M | −CHF 45.9M | CHF 53.3M | −CHF 61.2M | −CHF 68.3M | −CHF 74.8M | −CHF 61.2M | CHF 65.3M | −CHF 70.2M |
| Share buybacks | — | — | CHF 0 | CHF 0 | CHF 100.0K | CHF 0 | CHF 0 | — | — | — |
| Q2 FY23Jun 2023 | Q4 FY23Dec 2023 | Q1 FY24†Mar 2024 | Q2 FY24Jun 2024 | Q4 FY24Dec 2024 | Q1 FY25†Mar 2025 | Q2 FY25Jun 2025 | Q4 FY25Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | CHF 0 | — | CHF 0 | CHF 687.0K | — | CHF 990.0K | CHF 1.31M | — |
| Growth (year over year) | — | — | — | — | — | — | +90.1% | — |
| Operating income | −CHF 17.0M | — | −CHF 20.1M | −CHF 21.0M | — | −CHF 19.4M | −CHF 19.4M | — |
| Operating margin | — | — | — | −3051.1% | — | −1956.7% | −1484.5% | — |
| Net income | −CHF 16.8M | — | −CHF 17.9M | −CHF 22.8M | — | −CHF 19.0M | −CHF 21.2M | — |
| Net margin | — | — | — | −3313.0% | — | −1922.1% | −1622.4% | — |
| EPS (diluted) | −CHF 0.20 | — | −CHF 0.18 | −CHF 0.23 | — | −CHF 0.19 | −CHF 0.21 | — |
| Balance sheet | ||||||||
| Cash and equivalents | CHF 40.0M | CHF 78.5M | — | CHF 51.6M | CHF 36.3M | — | CHF 25.7M | CHF 26.8M |
| Total assets | CHF 156.2M | CHF 182.8M | — | CHF 237.5M | CHF 230.9M | — | CHF 190.2M | CHF 154.3M |
| Total liabilities | CHF 16.9M | CHF 22.2M | — | CHF 114.1M | CHF 118.6M | — | CHF 115.5M | CHF 109.4M |
| Shareholders' equity | CHF 139.3M | CHF 160.6M | — | CHF 123.4M | CHF 112.3M | — | CHF 74.7M | CHF 44.9M |
From AC Immune's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Amounts are in Swiss Franc (CHF), as reported, not converted to dollars. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning AC Immune in our feed yet.